Novartis Pharma AG is an operating company of Novartis AG, a Swiss pharmaceutical group headquartered in Basel. The company discovers, develops, manufactures, and commercializes prescription medicines and biologics, integrating discovery chemistry, process development, and large-scale production.
Its activities span small‑molecule and biologic R&D, active pharmaceutical ingredient (API) and finished‑dose manufacturing, and global supply chain operations. Core therapeutic areas include oncology, immunology, neuroscience, cardiovascular, renal and metabolic diseases, and ophthalmology. Novartis Pharma AG operates research and production sites across Europe, the Americas, and Asia, and collaborates with academic and industry partners for in‑licensing and co‑development.
Following the 2023 spin‑off of Sandoz, the group focuses on innovative pharmaceuticals rather than generics and biosimilars. For chemical industry stakeholders, Novartis Pharma AG is a significant developer and purchaser of advanced intermediates, APIs, and bioprocess technologies, with an emphasis on quality, regulatory compliance, and scalable manufacturing.
To provide comprehensive coverage, we aggregate data and news under the name Novartis, encompassing the following company names, divisions, and related entities:
Novartis AG and Novartis International AG.
This list encompasses current and former names, alternate names, and key divisions associated with Novartis, ensuring you can easily find all relevant information under a single, unified profile.